Vanguard Group Inc Sab Biotherapeutics, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.62 - $1.0 $11,900 - $19,194	19,194 Added 1.96%	996,132 $687,000
Q3 2023 Nov 14, 2023	BUY	$0.47 - $0.9 $6,674 - $12,780	14,200 Added 1.47%	976,938 $615,000
Q2 2023 Aug 14, 2023	BUY	$0.38 - $1.09 $99,238 - $284,657	261,154 Added 37.22%	962,738 $799,000
Q4 2022 Feb 10, 2023	BUY	$0.54 - $9.8 $313 - $5,693	581 Added 0.08%	701,584 $413,000
Q3 2022 Nov 14, 2022	SELL	$0.13 - $12.4 $2,684 - $256,035	-20,648 Reduced 2.86%	701,003 $491,000
Q2 2022 Aug 12, 2022	BUY	$1.11 - $3.46 $555 - $1,730	500 Added 0.07%	721,651 $1.05 Million
Q1 2022 May 13, 2022	BUY	$1.78 - $8.5 $67,958 - $324,521	38,179 Added 5.59%	721,151 $2.71 Million
Q4 2021 Feb 14, 2022	BUY	$7.3 - $11.24 $4.99 Million - $7.68 Million	682,972 New	682,972 $5.33 Million

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $111M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.